Loading
While patients are treated in a platform trial, their tumour cells grow in a dish and are tested against dozens of drug pairs. The pairs that win in the dish become the next arms.
Co-clinical organoid programmes (for example in pancreatic and colorectal cancer) have tested whether dish responses predict patient responses. The proposal inverts the use: a platform trial's organoid bank becomes a combination discovery engine, testing hundreds of pairs on the same tumours that are being treated, so the next arm is chosen from data on the trial population itself rather than on generic cell lines.
Shares Curesponse, SEngine Precision Medicine, Xilis, PDAC organoid pharmacotyping.
Shares Patient-derived organoids to pick ADC payloads, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Xilis, Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Curesponse, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Lab models that fail to predict what happens in patients, Too many combinations to test, Colorectal cancer.
Shares Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.